European Pharma Races to Catch Up with Data Protection
The European Union’s struggle to bring its data protection rules into the 21st century continues-haltingly-as the EU itself enters its new era, with a new European Parliament, a new President-designate of the European Commission, and a new European Commission due to take office in November.
The European Union’s struggle to bring its data protection rules into the 21st century continues-haltingly-as the EU itself enters its new era, with a new European Parliament, a new President-designate of the European Commission, and a new European Commission due to take office in November.
This has left the pharmaceutical sector, already out of breath from its struggles to catch up with data disclosure, in a new race-to avoid becoming a victim of excessive data protection. The latest entry in this race is a working group that the European Forum on Good Clinical Practice has set up to explore the issue from the perspective of research.
Peter O’Donnell outlines the working group’s efforts in this Applied Clinical Trials article.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
The 8 Market Access Performance Metrics You Should Be Tracking
March 25th 2025This guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.
